Keyphrases
Author Names
17%
Autologous Dendritic Cells
20%
Bevacizumab
44%
Bevacizumab Treatment
17%
Brain Tumor
29%
Central Nervous System Tumors
11%
Cerebrospinal Fluid
11%
Checkpoint Inhibitors
20%
Chemotherapy
38%
Concurrent Chemotherapy
12%
Concurrent Radiotherapy
12%
DCVax
17%
Dendritic Cell Vaccine
35%
Enzastaurin
17%
Enzyme-inducing Antiepileptic Drugs
12%
Geriatrics
62%
Glioblastoma
55%
Glioblastoma multiforme
34%
Head-and-neck Cancer
11%
High-grade Glioma
72%
Local Control
11%
Locally Advanced
15%
Magnetic Resonance Imaging
17%
Median Overall Survival
25%
Median Progression-free Survival
12%
Meningioma
26%
Newly Diagnosed Glioblastoma
50%
Older Cancer Patients
17%
Older Patients
55%
Overall Survival
35%
Phase I Trial
35%
Phase II Trial
46%
Phase III Clinical Trial
17%
Primary Brain Tumor
25%
Programmed Death-ligand 1 (PD-L1)
15%
Progression-free Survival
35%
Radiation Therapy
39%
Radiotherapy
73%
Randomized Phase II Trial
11%
Re-irradiation
55%
Re-resection
11%
Recurrent Glioblastoma
38%
Recurrent Glioma
11%
Standard of Care
38%
Stereotactic Radiosurgery
14%
Surgical Resection
13%
Temozolomide
24%
Tumor
41%
Tumor Progression
11%
Unfit for Surgery
26%
Medicine and Dentistry
Adverse Event
10%
Bevacizumab
30%
Chemotherapy
36%
Cisplatin
11%
Clinical Trial
34%
COVID-19
8%
Dendritic Cell
13%
Dendritic Cell Vaccine
27%
Diagnosis
10%
Disease
10%
Ganglioglioma
57%
Geriatrics
62%
Glioblastoma
90%
Gliosarcoma
8%
Head and Neck Cancer
10%
Image-Guided Radiation Therapy
10%
Immunotherapy
54%
Intention-to-Treat Analysis
13%
Intracranial Tumor
21%
Ketogenic Diet
8%
Lung Metastasis
8%
Malignant Neoplasm
22%
Medulloblastoma
10%
Meningioma
17%
Meningitis
8%
Neck
8%
Neoplasm
57%
Nephrectomy
8%
Octreotide
8%
Olradipine
8%
Overall Survival
38%
Panobinostat
8%
Phase I Trials
17%
Placebo
14%
Placebo-Controlled Study
8%
Progression Free Survival
27%
Quality of Life
11%
Radiation Therapy
98%
Randomized Clinical Trial
9%
Re-Irradiation
46%
Recurrent Disease
21%
Skin Carcinoma
8%
Stereotactic Body Radiation Therapy
8%
Surgery
26%
Targeted Therapy
8%
Temozolomide
15%
Trebananib
8%
Tumor Cell
9%
Tumor Progression
11%
Vocimagene Amiretrorepvec
8%
Pharmacology, Toxicology and Pharmaceutical Science
9 Aminocamptothecin
8%
Adverse Event
15%
Anticonvulsive Agent
21%
Astrocytoma
12%
Bevacizumab
37%
Blood-Brain Barrier
11%
Brain Metastasis
10%
Central Nervous System Tumor
9%
Chemotherapy
26%
Clinical Trial
14%
Dendritic Cell Vaccine
18%
Dexamethasone
11%
Disease
14%
DNA Methyltransferase
8%
Enzastaurin
17%
Glioblastoma
100%
Glioma
39%
Gliosarcoma
8%
Glucocorticoid
8%
Glutamate Receptor
8%
Intracranial Tumor
32%
Ipilimumab
8%
Irinotecan
8%
Lenalidomide
8%
Lomustine
8%
Malignant Neoplasm
11%
Maximum Tolerated Dose
8%
Melanoma
8%
Meningioma
8%
Meningitis
8%
Methotrexate
13%
Neoplasm
48%
Overall Survival
37%
Paclitaxel Poliglumex
8%
Panobinostat
8%
Phase I Trials
26%
Phase II Trials
18%
Placebo
14%
Placebo-Controlled Study
8%
Procarbazine
8%
Progression Free Survival
39%
Prospective Study
10%
Recurrent Disease
11%
Sialoprotein
8%
Talampanel
8%
Temozolomide
23%
Trebananib
8%
Tumor Growth
10%
Verubulin
8%
Vincristine
8%
